Clinical Trial: Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients

Brief Summary: In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.

Detailed Summary:
Sponsor: European Institute of Oncology

Current Primary Outcome: Incidence of chemotherapy-induced cardiotoxicity [ Time Frame: 12 month period ]

Original Primary Outcome: Incidence of chemotherapy-induced cardiotoxicity

Current Secondary Outcome: Major adverse cardiac events, including death. [ Time Frame: 12 month period ]

Original Secondary Outcome: Major adverse cardiac events, including death.

Information By: European Institute of Oncology

Dates:
Date Received: February 15, 2006
Date Started: November 2000
Date Completion:
Last Updated: February 7, 2017
Last Verified: February 2017